Assay Detail
Binding
CHEMBL5657788
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of human ERK8 in presence of ATP by by radiometric kinase assay
1
Total Activities
1
Compounds Tested
1
Activity Types
2
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 1 | 6.89 | 6.89 |
Assay Parameters
| Parameter | Type | Value | Units | Text |
|---|---|---|---|---|
| EFO_ID | EFO_ID | - | — | EFO:1001938 |
| EFO_TERM | EFO_TERM | - | — | b-cell non-hodgkins lymphoma |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4169078 | SRA-737 | 1.0 | 1 | 6.89 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4169078 | SRA-737 | IC50 | = | 130.0 | nM | 6.89 |